SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of October 5, 2026 in ARS Pharmaceuticals Inc. Lawsuit - SPRY

A securities class action has been filed on behalf of shareholders who purchased ARS Pharmaceuticals Inc. (NASDAQ: SPRY ) securities between March 9, 2026 and June 24, 2026. The lawsuit alleges that ARS Pharmaceuticals built analyst expectations on a July 1, 2026 coverage timeline that was never disclosed as at risk of slipping to January 2027. SPRY closed at $10.54 on June 24, 2026 and fell to $8.02 the next session, a one-day decline of $2.52 per share, or 23.9%, after the Company announced that no new commercial formulary additions or coverage decisions had been issued for neffy in the July 1, 2026 cycle.

Wall Street Reassessment: Analyst Opinion Evolution on SPRY Coverage indicated that expanded payer access was the single most-watched catalyst for the epinephrine nasal spray. William Blair wrote that the absence of a CVS Caremark formulary addition "came as a negative shock given management's prior guidance towards reaching a potential agreement in time and updates suggesting positive progress on the contract," adding that CVS "remains the only major PBM without unrestricted coverage" and that the timing meant neffy "won't be on formulary with CVS for this year's back-to-school season." The firm lowered its estimates to reflect that impact.

Analyst Coverage Timeline March 9, 2026: On the fourth quarter earnings call, an Oppenheimer analyst asked directly about the timing of expanded unrestricted access; management responded that Caremark "has a very rigid system" and had set the date at July 1. March 9, 2026: The Company reported approximately 93% overall commercial coverage, with roughly 57% of covered lives having access without prior authorization. May 15, 2026: Management told analysts a proposal removing the prior authorization requirement and targeting a July 1 effective date was "in the final stages of the formulary approval process." June 24, 2026 (after the close): ARS disclosed no July 1 cycle coverage decision; CVS Caremark reserved its decision until January 2027. June 25, 2026: Shares closed at $8.02, down 23.9%, as analysts cut estimates tied to the lost summer and back-to-school seasons.

The complaint alleges that ARS's public statements did not adequately disclose the risk that Caremark's process could push a decision past the July 1 date, and that estimates and share prices built on that timeline were correspondingly inflated. Approval rates for plans still requiring prior authorization were disclosed at approximately 55%, underscoring why analysts treated unrestricted access as the key adoption variable.